2021
DOI: 10.1016/j.pharmthera.2020.107711
|View full text |Cite
|
Sign up to set email alerts
|

Myeloperoxidase: A versatile mediator of endothelial dysfunction and therapeutic target during cardiovascular disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
36
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 41 publications
(37 citation statements)
references
References 614 publications
0
36
0
Order By: Relevance
“…However, all five peptides could form hydrophobic interactions with one of the catalytic residues (Arg239) of MPO. Besides, all five peptides could interact with the heme group (Hec606) through hydrophobic interactions ( Table 2 ); the heme group is a cofactor in the active site of MPO [ 42 ]. Based on the interactions with both catalytic residue Arg239 and the heme group of MPO, all the five peptides are potential MPO inhibitors.…”
Section: Resultsmentioning
confidence: 99%
“…However, all five peptides could form hydrophobic interactions with one of the catalytic residues (Arg239) of MPO. Besides, all five peptides could interact with the heme group (Hec606) through hydrophobic interactions ( Table 2 ); the heme group is a cofactor in the active site of MPO [ 42 ]. Based on the interactions with both catalytic residue Arg239 and the heme group of MPO, all the five peptides are potential MPO inhibitors.…”
Section: Resultsmentioning
confidence: 99%
“…Recent studies have pointed to several MPO inhibitors for the prevention and treatment of atherosclerotic cardiovascular disease, such as PF-1355, AZM198, azo radical, and thiocyanate ( 29 ). Targeting MPO has the potential to become one of the most promising therapies for coronary heart disease and other atherosclerotic cardiovascular diseases, such as PF-06282999 ( 8 ), which has effective and selective MPO inhibition properties, and has been advanced into clinical trials in human pharmacokinetics, safety, tolerance, and MPO inhibition studies ( 30 ). However, there are still some challenges to consider in the application of MPO inhibitors.…”
Section: Discussionmentioning
confidence: 99%
“…Activated and invading/recruited neutrophils (containing up to 5% MPO of total cell protein content) play potential roles in the initiation and progression of atherosclerosis and other CVDs [ 9 , 69 ] including cardiac damage [ 3 , 70 ]. Thus, MPO has gained significant attention as an oxidative mediator of reperfusion injury, adverse ventricular remodelling, and atrial fibrillation [ 3 ].…”
Section: Discussionmentioning
confidence: 99%